Company Lantheus Holdings, Inc.

Equities

LNTH

US5165441032

Medical Equipment, Supplies & Distribution

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Ratings for Lantheus Holdings, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Diagnostic & Testing Substances

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
63.81 ^USD	+2.37%		+4.97%	+2.92%

Apr. 18	B. Riley Raises Price Target on Lantheus Holdings to $99 From $95, Keeps Buy Rating	MT
Mar. 07	Lantheus Holdings Insider Sold Shares Worth $262,005, According to a Recent SEC Filing	MT

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others.

Number of employees: 834

USD in Million	2022	Weight	2023	Weight	Delta
PYLARIFY 65.7 %	527	56.4 %	851	65.7 %	+61.41%
DEFINITY 21.6 %	245	26.2 %	280	21.6 %	+14.19%
TechneLite 6.7 %	89	9.5 %	87	6.7 %	-1.68%
Strategic Partnerships and Other 4.0 %	47	5.0 %	52	4.0 %	+10.68%
Other Precision Diagnostics 1.8 %	23	2.4 %	23	1.8 %	+0.68%
Other Radiopharmaceutical Oncology 0.2 %	4	0.4 %	3	0.2 %	-23.70%

USD in Million	2022	Weight	2023	Weight	Delta
United States 97.4 %	901	96.4 %	1,263	97.4 %	+40.08%
International 2.6 %	34	3.6 %	34	2.6 %	+0.13%

Managers	Title	Age	Since
Brian Markison CEO	Chief Executive Officer	64	12-08-31
Paul Blanchfield PSD	President	43	20-01-26
Robert Marshall DFI	Director of Finance/CFO	57	18-09-20
Mary Heino CHM	Chairman	64	13-03-31
Iryna Teslenko CTO	Chief Tech/Sci/R&D Officer	-	21-04-06
Bela Denes CTO	Chief Tech/Sci/R&D Officer	-	21-04-06
Jean-Claude Provost CTO	Chief Tech/Sci/R&D Officer	60	22-04-03
Daniel Niedzwiecki ADM	Chief Administrative Officer	47	13-08-31
Mark Kinarney IRC	Investor Relations Contact	-	17-12-31
Linda S. Lennox IRO	Public Communications Contact	59	20-07-31

Members of the board	Title	Age	Since
Brian Markison CEO	Chief Executive Officer	64	12-08-31
James H. Thrall BRD	Director/Board Member	80	18-01-31
Sam Leno BRD	Director/Board Member	78	12-04-30
Mary Heino CHM	Chairman	64	13-03-31
Gary Pruden BRD	Director/Board Member	61	18-01-31
Julie McHugh BRD	Director/Board Member	59	16-12-31
Minnie Baylor-Henry BRD	Director/Board Member	76	22-01-31
Gérard Ber BRD	Director/Board Member	66	20-06-18
Heinz Christoph Mäusli BRD	Director/Board Member	61	20-06-18

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	69,890,404	66,792,244 ( 95.57 %)	1,339,000 ( 1.916 %)	95.57 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 11.56 %	7,923,422	11.56 %	493 M $
Vanguard Fiduciary Trust Co. 10.18 %	6,973,141	10.18 %	434 M $
Janus Henderson Investors US LLC 5.761 %	3,947,571	5.761 %	246 M $
STATE STREET CORPORATION 3.501 %	2,398,859	3.501 %	149 M $
Fidelity Management & Research Co. LLC 3.402 %	2,331,134	3.402 %	145 M $
AllianceBernstein LP 2.903 %	1,989,572	2.903 %	124 M $
T. Rowe Price International Ltd. 2.384 %	1,633,869	2.384 %	102 M $
Westfield Capital Management Co. LP 2.281 %	1,563,181	2.281 %	97 M $
Geode Capital Management LLC 2.224 %	1,523,824	2.224 %	95 M $
Reinhart Partners, Inc. 2.146 %	1,470,383	2.146 %	92 M $

Name	Equities	%	Valuation
PERSPECTIVE THERAPEUTICS, INC. 19.90%	116,773,394	19.90%	138,960,339 $

Lantheus Holdings, Inc.

201 Burlington Road South Building

01730, Bedford

+978 671 8001

http://www.lantheus.com

Name	Category and Sector
Lantheus Medical Imaging, Inc. Lantheus Medical Imaging, Inc. Medical SpecialtiesHealth Technology Lantheus Medical Imaging, Inc. engages in the manufacture, marketing, sale, and distribution of medical imaging products. It provides diagnostic imaging and nuclear medicine products that assist clinicians with the detection of disease, primarily cardiovascular. Its product protfolio includes DEFINITY, TechneLite, Xenon, AZEDRA, Cardiolite, and NEUROLITE. The company was founded in 1956 and is headquartered in North Billerica, MA.	Medical Specialties

Name

Category and Sector

Medical Specialties

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

63.81 USD

Average target price

94.11 USD

Spread / Average Target

+47.49%

Consensus

Estimates Revisions

Company calendar

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Diagnostic & Testing Substances

	1st Jan change	Capi.
LANTHEUS HOLDINGS, INC.	+2.92%	4.37B
BIOMÉRIEUX	-1.04%	12.55B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-17.29%	7.02B
DIASORIN S.P.A.	-2.21%	5.19B
AUTOBIO DIAGNOSTICS CO., LTD.	-4.79%	4.35B
10X GENOMICS, INC.	-50.07%	3.33B
ANDON HEALTH CO., LTD.	+7.65%	2.62B
VITROLIFE AB	-15.92%	2.03B
MYRIAD GENETICS, INC.	-3.34%	1.67B
SHANGHAI RUNDA MEDICAL TECHNOLOGY CO., LTD.	-13.66%	1.45B

Diagnostic & Testing Substances